scholarly journals Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

Cancer ◽  
2011 ◽  
Vol 118 (7) ◽  
pp. 1946-1954 ◽  
Author(s):  
Jenny J. Kim ◽  
Susan A.J. Vaziri ◽  
Brian I. Rini ◽  
Paul Elson ◽  
Jorge A. Garcia ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Single Nucleotide Polymorphisms ◽  
Clinical Outcome ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Nucleotide Polymorphisms ◽  
Cell Renal Cell Carcinoma ◽  
Single Nucleotide

scholarly journals Single Nucleotide Polymorphisms in the Wilms’ Tumour Gene 1 in Clear Cell Renal Cell Carcinoma

PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e58396 ◽  
Author(s):  
Xingru Li ◽  
Sihan Wang ◽  
Raviprakash T. Sitaram ◽  
Charlotta Andersson ◽  
Börje Ljungberg ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Single Nucleotide Polymorphisms ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Nucleotide Polymorphisms ◽  
Wilms Tumour ◽  
Cell Renal Cell Carcinoma ◽  
Single Nucleotide

scholarly journals Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib

Kidney Cancer ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 139-149
Author(s):  
Benoit Beuselinck ◽  
Thomas Van Brussel ◽  
Annelies Verbiest ◽  
Maxime Vanmechelen ◽  
Gabrielle Couchy ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Single Nucleotide Polymorphism ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Validation Cohort ◽  
Clear Cell ◽  
Nucleotide Polymorphism ◽  
Discovery Cohort ◽  
Cell Renal Cell Carcinoma ◽  
Single Nucleotide

BACKGROUND: Previously, we have shown a correlation between single nucleotide polymorphism (SNP) rs307826 in vascular endothelial growth factor receptor-3 (VEGFR3) and outcome in metastatic clear-cell renal cell carcinoma (m-ccRCC) patients treated with sunitinib. OBJECTIVE: We aimed to validate this finding in an independent patient series. METHODS: m-ccRCC patients receiving sunitinib as first-line targeted therapy were included in a validation cohort. Endpoints were response rate (RR), progression-free survival (PFS) and overall survival (OS). We also updated survival data of our discovery cohort as described previously. RESULTS: Eighty-four patients were included in the validation cohort. rs307826 AG/GG-carriers had a shorter PFS (8 versus 12 months, p = 0.04) and a trend towards a shorter OS (18 versus 27 months, p = 0.22) compared to AA-carriers. In the total series of 168 patients (from the discovery cohort, as described previously, and the validation cohort), rs307826 AG/GG-carriers had a poorer RR (29% versus 53%, p = 0.008), PFS (8 versus 15 months, p = 0.0002) and OS (22 versus 31 months, p = 0.004) compared to AA-carriers. rs307826 was independently associated with PFS and OS on multivariate analysis. CONCLUSION: VEGFR3 rs307826 seems to be associated with outcome on sunitinib in m-ccRCC. Its impact highlights the role of VEGFR3 in ccRCC pathogenesis and as a target of sunitinib.

scholarly journals Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (63) ◽  
pp. 106551-106564 ◽  
Author(s):  
Carmen Garrigós ◽  
Marta Espinosa ◽  
Ana Salinas ◽  
Ignacio Osman ◽  
Rafael Medina ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Single Nucleotide Polymorphisms ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Biomarkers ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide
Sign in / Sign up

Export Citation Format

Share Document